Skip to content

Development and Clinical Application of a Novel Imaging Grading System for Pheochromocytoma and Paraganglioma (PPGL)

Development and Clinical Application of a Novel Imaging Grading System for Pheochromocytoma and Paraganglioma (PPGL)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07412158
Enrollment
500
Registered
2026-02-17
Start date
2017-01-01
Completion date
2025-12-01
Last updated
2026-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pheochromocytoma and Paraganglioma (PPGL), Quantitative Assessment, Risk Grading System

Brief summary

This study aims to develop and preliminarily validate an anatomy-morphological risk grading system (IUPU-PPGL Grading) based on preoperative imaging 3D reconstruction, in order to quantitatively assess surgical complexity and perioperative safety in PPGL patients, and to evaluate the value of this grading system for formulating individualized surgical strategies.

Interventions

observational diagnostic model development

Sponsors

Peking University First Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* ① Patients who underwent curative surgical resection (including laparoscopic, robot-assisted, or open surgery) at our hospital within the study period; * Postoperative pathological confirmation of PPGL; * Availability of complete preoperative imaging data; ④ Availability of complete perioperative clinical data, including anesthesia records, surgical records, and postoperative hospitalization information; ⑤ Age ≥ 18 years.

Exclusion criteria

* ① Lack of key imaging data or poor image quality that could not meet evaluation requirements; * Requirement for concurrent complex surgery for other diseases, making it difficult to independently assess perioperative indicators; ③ History of biopsy only, exploratory surgery, or presence of recurrence, bilateral, or multifocal lesions, preventing independent evaluation; ④ Primary tumors located in special sites (e.g., pelvic, bladder, spermatic cord, or other rare extra-adrenal locations), leading to incomparable surgical approaches and perioperative outcomes.

Design outcomes

Primary

MeasureTime frame
Operative TimeIntraoperative

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026